Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: MK0767

Study type

Interventional

Funder types

Industry

Identifiers

NCT00543751

2007_634

0767-025

MK-0767-025

Details and patient eligibility

About

The purpose of this study is to compare how MK0767 and metformin and sulfonylurea therapy lower blood glucose in patients with inadequate glycemic control This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment

610 patients

Sex

All

Ages

21 to 78 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with Type 2 diabetes wtih inadequate glycemic control on maximally effective/tolerated metformin and sulfonylurea therapy
Non-pregnant females

Exclusion criteria

Patients with Type 1 Diabetes or history of ketoacidosis
Patients who have been treated with insulin or other antihyperglycemic agents
Patients with viral hepatitis, active liver or gallbladder disease, history of pancreatitis, heart disease, congestive heart failure, inadequately controlled hypertension, HIV positive, history hematologic disorders or neoplastic disease